ID: ALA5280999

Max Phase: Preclinical

Molecular Formula: C15H13FO3

Molecular Weight: 260.26

Associated Items:

Representations

Canonical SMILES:  CCOC(=O)c1ccc(-c2cccc(F)c2)cc1O

Standard InChI:  InChI=1S/C15H13FO3/c1-2-19-15(18)13-7-6-11(9-14(13)17)10-4-3-5-12(16)8-10/h3-9,17H,2H2,1H3

Standard InChI Key:  SPPPCTKJCGJYIY-UHFFFAOYSA-N

Associated Targets(Human)

Transient receptor potential cation channel subfamily M member 8 1168 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 260.26Molecular Weight (Monoisotopic): 260.0849AlogP: 3.38#Rotatable Bonds: 3
Polar Surface Area: 46.53Molecular Species: NEUTRALHBA: 3HBD: 1
#RO5 Violations: 0HBA (Lipinski): 3HBD (Lipinski): 1#RO5 Violations (Lipinski): 0
CX Acidic pKa: 9.53CX Basic pKa: CX LogP: 4.47CX LogD: 4.47
Aromatic Rings: 2Heavy Atoms: 19QED Weighted: 0.86Np Likeness Score: -0.63

References

1. Bianchini G, Tomassetti M, Lillini S, Sirico A, Bovolenta S, Za L, Liberati C, Novelli R, Aramini A..  (2021)  Discovery of Novel TRPM8 Blockers Suitable for the Treatment of Somatic and Ocular Painful Conditions: A Journey through pKa and LogD Modulation.,  64  (22): [PMID:34762442] [10.1021/acs.jmedchem.1c01647]

Source